NCT02729025View on ClinicalTrials.gov

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

PHASE3CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

April 5, 2018

Study Completion Date

April 5, 2018

Conditions
Subjects With Hyperlipidemia, Dyslipidemia
Interventions
DRUG

Evolocumab

Administered subcutaneously once a month using an autoinjector/pen.

DRUG

Placebo

Administered subcutaneously once a month using an autoinjector/pen.

Trial Locations (15)

19141

Research Site, Philadelphia

28117

Research Site, Mooresville

33144

Research Site, Miami

76054

Research Site, Hurst

89118

Research Site, Las Vegas

L3Y 5G8

Research Site, Newmarket

M9V 4B4

Research Site, Toronto

G7H 7K9

Research Site, Chicoutimi

G1V 4W2

Research Site, Québec

1105 AZ

Research Site, Amsterdam

7334 DZ

Research Site, Apeldoorn

6525 GA

Research Site, Nijmegen

3015 CE

Research Site, Rotterdam

5912 BL

Research Site, Venlo

5141 BM

Research Site, Waalwijk

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02729025 - Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) | Biotech Hunter | Biotech Hunter